key: cord-1032672-3enns3z8 authors: Abu Jabal, K.; Ben Amram, H.; Beiruti, K.; Brimat, I.; Abu Saada, A.; Bathish, Y.; Sussan, C.; Zarka, S.; Edelstein, M. title: SARS-CoV-2 Immunogenicity in individuals infected before and after COVID-19 vaccination: Israel, January-March 2021: Implications for vaccination policy date: 2021-04-16 journal: nan DOI: 10.1101/2021.04.11.21255273 sha: cabce0de7d010ab3159e7f5a4a5d5454a71dd268 doc_id: 1032672 cord_uid: 3enns3z8 Between December 2020-March 2021 we measured anti-SARS-CoV-2 IgG titers post-vaccination with the BNT162b2 vaccine among 725 Israeli hospital workers. Previously infected individuals who received one dose had higher IgG titres than fully vaccinated, never-infected workers. Post-vaccination infection did not increase IgG titres. Individuals infected post-dose one should receive the second. post-vaccination with the BNT162b2 vaccine among 725 Israeli hospital workers. Previously infected individuals who received one dose had higher IgG titres than fully vaccinated, never-infected workers. Post-vaccination infection did not increase IgG titres. Individuals infected post-dose one should receive the second. As of March 2021, Israel was the country with the highest COVID19 vaccine coverage1). It used the BNT162b2 vaccine, an mRNA vaccine over 90% effective against clinical disease (2, 3) , and possibly against infection (4) . As of March 29 th 2021, 51% of the population had received two doses (5) . The impact of vaccination on SARS-CoV-2 transmission is now clearly seen, with a gradual decrease of the basic reproduction ratio (R 0 ), which stood at 0.5 on March 19 th (5) despite a gradual easing of social distancing measures since the beginning of March 2021. In Israel, individuals previously infected with SARS-CoV-2 were not eligible for vaccination until early March 2021. The duration of immunity following natural infection remains unknown but evidence shows that despite rapid waning of antispike SARS-CoV-2 IgG antibodies following natural infection (6) , memory B cells persist at least 8 months (7) . Vaccinating previously infected individuals with a single dose of BNT162b2 vaccine generates a boost-type IgG response up to 10 months post-infection (8) . As a result, some countries including Israel now recommend a . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.11.21255273 doi: medRxiv preprint single dose of vaccine in infected individuals (9) . The benefit of the second dose in such individuals remains uncertain. Vaccine efficacy from a single dose of the BNT162b2 vaccine in uninfected individuals begins 14 days post-vaccination and reaches 50-80% between days 15-35) (2) . Therefore, a proportion of patients will be infected after vaccination, mostly within the first 14 days post-vaccination. In Israel these individuals are not offered a second dose, based on the assumption that one dose confers immunity in infected individuals. However, immunogenicity in patients infected after one dose of vaccine has not been evaluated. Our aim was to measure Anti-spike IgG response in a cohort of vaccinated healthcare workers according to SARS-CoV2 infection status (never infected or infected before or after vaccination) in order to inform vaccination policy. All employees of Ziv Medical Centre (ZMC), a hospital in Northern Israel, were offered vaccination with the BNT162b2 vaccine from December 2020. Before vaccination, Nucleocapsid (N) IgG antibody levels were measured in consenting workers, using a highly sensitive and specific SARS-CoV-2 IgG qualitative assay (Abbott, Abbot Park, US) (10), followed by a quantitative LIAISON SARS-CoV-2 S1/S2 IgG PCR test (DiaSorin, Saluggia, Italy) for verification purposes (10) . Workers were also asked about evidence of previous infection with SARS-CoV-2. All the individuals with detectable IgG antibodies at baseline and/or evidence of a previous positive PCR test SARS-CoV-2 were considered previously infected. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.11.21255273 doi: medRxiv preprint AntiSARS-CoV-2 spike IgG levels were measured twice: around 21 days (range 15-35 days) and around 51 days (range 41-65 days) post-dose one, using the LIAISON Diasorin SARS-CoV-2 S1/S2 IgG assay (10) . All workers who developed COVID19-compatible symptoms during the study period Of approximately 1,500 employees, 725 received at least one dose of vaccine and were tested at least once post-vaccination. Of these, 25 had evidence of prevaccination infection and 35 had evidence of infection post-dose 1 (Table) , of which 32 before they were eligible for dose 2. These 32 individuals did not receive dose 2 as they were no longer eligible owing to their infected status. Not all these patients were tested twice (table). Compared with uninfected individuals, previously infected individuals who received one vaccine dose had high IgG titers at 21 days post-vaccine that remained high approximately 50 days post-vaccination (table), more than twice higher than . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.11.21255273 doi: medRxiv preprint Individuals infected with SARS-CoV-2 pre-vaccination have a strong and persisting response after one BNT162b2 dose. Dose 2 in those individuals has no impact on IgG titers. Several countries, including France and Israel recommend one vaccine dose for these individuals. Our data supports this policy. Our study shows that when it comes to vaccinating infected individuals, the sequence of events matters. Individuals infected post-vaccination had IgG titers at 21 and 50 days similar to those never infected who received the same number of doses and much lower than those infected pre-vaccination. Individuals infected after a single dose of the Pfizer vaccine should therefore remain eligible for a second dose to ensure adequate protection levels. This implies a change in vaccination policy in many countries including Israel. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.11.21255273 doi: medRxiv preprint Our study presents limitations. First, our numbers are small. Notably, most previously infected who received one dose were not tested again at 50 days. Very few patients were infected after receiving their second dose, a finding compatible with the high effectiveness of the vaccine (3). Second, post-vaccination testing was symptombased, and we could not detect asymptomatic patients infected post-vaccination. Our study focuses on the BNT162b2 vaccine and it is possible that these findings are not relevant to other vaccines. Lastly, our study measures circulating antibody levels and does not measure other components of the immune system. Interpreting the clinical significance of difference in IgG levels in the absence of correlates of protection remains a challenge. Nevertheless, this study demonstrates no benefit in receiving a second dose among individuals infected prior to vaccination, and more importantly, that infection after vaccination (dose 1 or dose 2) seems to have very little effect on immunogenicity. It is therefore important to not assume that individuals infected after their first dose are fully immune-these individuals need to receive a second dose of COVID-19 vaccine. Our world in data Coronavirus (COVID-19) Vaccinations -Statistics and Research -Our World in Data the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 16 Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight Ministry of Health of Israel Jerusalem: Ministry of Health Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: realworld evidence from healthcare workers, Israel International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Vaccination strategie against SARS-CoV-2-vaccination of individuals with a history of COVID-19 infection Available from: Haute Autorité de Santé -Stratégie de vaccination contre le SARS-CoV-2 -Vaccination des personnes ayant un antécédent de Covid-19 (has-sante Funding: no external funding was received Conflct of interest: the authors declare no conflict of interest Biographical Sketch: Dr Kamal Abu Jabal is an internal medicine specialist since International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.11.21255273 doi: medRxiv preprint